Effect of atorvastatin on osteopontin of patients with chronic heart failure
10.3760/cma.j.issn.1008-6315.2014.04.013
- VernacularTitle:阿托伐他汀对慢性心力衰竭患者血浆骨桥蛋白的影响
- Author:
Guibin SHEN
;
Lihua ZHANG
- Publication Type:Journal Article
- Keywords:
Atorvastatin;
Plasma osteopontin;
Plasma N-terminal brain natriuretic peptide;
C-reactive protein;
Heart failure
- From:
Clinical Medicine of China
2014;30(4):376-378
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate atorvastatin administration on osteopontin and cardiac function of patients with chronic heart failure(CHF).Methods Sixty CHF patients were randomly divided into control (30 cases) and atorvastatin groups (30 cases).Patients in control group were given regular treatment including conventional oxygen inhalation,digitalis,angiotensin converting enzyme inhibitors,β blockers,diuretics,vasodilator therapy.Patients in treatment group were given atorvastatin at dose of 20 mg/d for 2 months plus regular treatment.The NHYA cardiac function,echocardiography determination of left ventricular ejection fraction(LVEF) were recorded.The levels of plasma osteopontin,plasma N-terminal brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) were measured.Results The levels of plasma osteopontin,NT-proBNP and CRP in atorvastatin group were (1 062.68 ± 130.63) ng/L,(609.00 ±62.39) ng/L and ((5.84 ± 0.70) mg/L respectively,lower than those of control group ((1609.94 ± 201.87) ng/L,(922.33 ± 108.68) ng/L,(8.90 ± 0.86) mg/L),and the differences were statistically significant (Z =-1.981,t =2.766,Z =-2.092,P ＜0.05).LVEF in atorvastatin group was (58.7 ± 1.2)％,higher than that in control group ((52.8 ± 1.6) ％ ; P ＜ 0.05).Conclusion Atorvastatin treatment can decrease plasma osteopontin density,alleviate the inflammatory response and inhibit cardiac remodeling in patients with heart failure,which was good for recovery of heart failure.
